Vedanta Biosciences CEO Receives 2019 Immigrant Entrepreneur Award
30 Octubre 2019 - 5:00AM
Business Wire
Vedanta Biosciences, a clinical-stage company developing a new
category of therapies for immune-mediated diseases based on defined
bacterial consortia, is pleased to announce that its co-founder and
CEO Bernat Olle, Ph.D., received the 2019 Barry M. Portnoy
Immigrant Entrepreneur Award from The Immigrant Learning Center in
the Life Science Business category. This award honors the
outstanding contributions of immigrant entrepreneurs who have built
successful businesses in Massachusetts, including their impact on
the innovation economy and service to local neighborhoods.
“I am honored to be recognized with this award,” Dr. Olle said.
“Vedanta Biosciences has benefited enormously from access to a
global talent pool in Massachusetts, where entrepreneurial and
skilled immigrants from around the world are welcomed.”
Dr. Olle was previously named "Innovator of the Year" in MIT
Technology Review Spain's "Innovators under 35" awards in 2013, and
a “40 under 40” honoree by Boston Business Journal in 2018. Vedanta
was also included on FierceBiotech’s Fierce 15 list in 2016.
About Vedanta Biosciences Vedanta Biosciences is a
clinical-stage microbiome leader developing a new category of
therapies for immune-mediated diseases based on rationally-defined
consortia of human microbiome-derived bacteria. Vedanta’s
proprietary capabilities include what is believed to be the largest
collection of human-gut associated bacteria, assays and
bioinformatics techniques for consortia design and optimization,
vast datasets from human interventional studies and facilities for
cGMP-compliant manufacturing of rationally-defined bacterial
consortia in powder form.
Vedanta Biosciences' pioneering work, in collaboration with its
scientific co-founders, has led to the identification of human
commensal bacteria that induce a range of immune responses –
including induction of regulatory T cells, CD8+ T cells, and Th17
cells, among others. These advances have been published in leading
peer-reviewed journals, including Science (multiple), Nature (2013,
2019), Cell, and Nature Immunology. Vedanta Biosciences has
harnessed these biological insights and its capabilities to
generate a pipeline of investigational live biotherapeutic products
(LBPs) in infectious disease, autoimmune disease, allergy, and
immuno-oncology. This pipeline includes three clinical-stage
product candidates currently being evaluated for the treatment of
recurrent C. difficile infection and inflammatory bowel disease (in
collaboration with Janssen Biotech, Inc.), and food allergy, as
well as a fourth product candidate expected to enter the clinic in
2019 in patients with advanced or metastatic cancers (in
combination with Bristol-Myers Squibb’s checkpoint inhibitor
OPDIVO®).
Vedanta’s IP portfolio contains over 30 issued patents with
coverage extending to 2037. Vedanta Biosciences was founded by
PureTech Health (LSE:PRTC). Its scientific co-founders are
world-renowned experts in immunology and microbiology who have
pioneered the fields of innate immunity, Th17 and regulatory T cell
biology.
Forward Looking Statement This press release contains statements
that are or may be forward-looking statements, including statements
that relate to the company's future prospects, developments, and
strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from current expectations,
including, but not limited to, those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191030005037/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com U.S. media Tom Donovan +1 857 559
3397 tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De May 2023 a May 2024